Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele...

EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5...

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The...

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma ( Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark )

Real world evidence on the use of antibody drug conjugates in peripheral T-cell...

Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut...

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP...

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

Can multiple endpoints in MM clinical papers create new insights?

Prof Evangelos Terpos and Prof Nina Shah

Can multiple endpoints in MM clinical papers create new insights? ( Prof Evangelos Terpos and Prof Nina Shah )

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

More from ecancer